Is supplemental ultrasonography a valuable addition to breast cancer screening for women with dense breasts?

The benefit is small and the cost is high, according to this comparative modeling study. Supplemental ultrasonography after a negative mammogram in women aged 50 to 74 with dense breasts prevented 0.36 breast cancer deaths (range across three simulation models, 0.14–0.75) and gained 1.75 quality-adjusted life years (QALYs) (range, 0.9–4.7) for every 1,000 women, compared with screening mammography alone. Supplemental ultrasonography also prompted 354 biopsy recommendations after a false-positive ultrasonography report (range, 345 to 421) per 1,000 women, compared with screening mammography alone.

The cost-effectiveness ratio for supplemental ultrasonography was $325,000 per QALY gained (range, $112,000–$766,000). When women with extremely dense breasts were analyzed separately, the cost per QALY gained was $246,000 (range, $74,000–$535,000).

Compared with women with less breast density, there is decreased cancer detection (sensitivity) with screening mammography.

Women with dense breasts have an increased lifetime risk of breast cancer. Because nearly half of women in the United States undergoing screening mammography have dense breasts, it is vital that we provide them with accurate and useful counseling.

The challenge of managing women with dense breasts has become complicated by the fact that 21 states have passed laws requiring that women with dense breasts be informed through scripted messages of the decreased sensitivity of screening and increased risk of cancer and advised to...
discuss with their provider whether additional testing (eg, with supplemental ultrasound) should be ordered. These laws may be well-intentioned, but they are problematic.

Although there are data documenting increased cancer detection with screening ultrasonography, there are no data currently available demonstrating that this increased detection adds value by improving important outcomes like disease-specific mortality. Further, the value proposition (improved outcomes/cost) of screening ultrasonography is unknown.

In this article, Sprague and colleagues attempt to fill this void by assessing the potential benefits, harms, and cost-effectiveness of supplemental ultrasonography following a negative screening mammogram for women with dense breasts.

Through the use of validated micro-simulation modeling, they calculate that the routine use of supplemental ultrasonography in women with dense breasts might result in 0.36 fewer deaths per 1,000 women screened. Compare this to 6 fewer deaths per 1,000 women undergoing screening mammography.

Moreover, the specificity of supplemental ultrasonography in this setting is poor, with 94% of recommended biopsies yielding benign findings (ie, positive predictive value of 6%).

References

WHAT THIS EVIDENCE MEANS FOR PRACTICE
At present, there is little evidence that routine supplemental ultrasonography improves important outcomes such as disease-specific mortality at a rational cost. However, there may be hope on the horizon: Emerging data suggest that digital tomosynthesis as a primary screening modality may improve both specificity and sensitivity, compared with mammography, in women with dense breasts.

Initial experience with tomosynthesis demonstrates both fewer callbacks and improved cancer detection in women, compared with screening mammography. However, the value proposition of this new technology will ultimately depend on a careful analysis of its effect on mortality and cost.

MARK D. PEARLMAN, MD

READ MORE about breast cancer screening, at obgmanagement.com

›› Does screening mammography save lives?
Janelle Yates, Senior Editor (April 2014)

›› Best age to begin screening mammograms: How I manage my patients
Andrew M. Kaunitz, MD (November 2013)

›› Which women are most likely to die from breast cancer—those screened annually starting at age 40, biennially starting at age 50, or not at all?
Mark D. Pearlman, MD (November 2013)

›› Do cosmetic breast implants hinder the detection of malignancy and reduce breast-cancer specific survival?
Andrew M. Kaunitz, MD (July 2013)

›› Your menopausal patient’s breast biopsy reveals atypical hyperplasia
JoAnn V. Pinkerton, MD (May 2013)